Absorption enhancers in pulmonary protein delivery

Journal of Controlled Release

Volumn 94, Issue 1, 2004, Pages 15-24

  Hussain, Alamdar ^a   Arnold, John J ^b   Khan, Mansoor A ^a   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Absorption enhancer promoter; Bioavailability; Proteins; Pulmonary route; Toxicity

Indexed keywords

ABSORPTION; ENZYME KINETICS; LIPIDS; MACROMOLECULES; NONINVASIVE MEDICAL PROCEDURES; PROTEINS; PULMONARY DISEASES; TOXICITY;

BIOAVAILABILITY; INJECTION-FREE ADMINISTRATION;

DRUG DOSAGE;

BACITRACIN; CASTOR OIL; GLYCOCHOLATE SODIUM; INSULIN; LANTHANIDE; LAURYL BETA DEXTRO MALTOSIDE; LINOLEIC ACID; LIPOSOME; MALTOSE; NAFAMSTAT MESILATE; OLEATE SODIUM; OLEIC ACID; OLEIC ACID ETHYL ESTER; OLEYL ALCOHOL; PALMITIC ACID; PALMITOLEIC ACID; PENETRATION ENHANCING AGENT; PHOSPHATIDYLCHOLINE; PLASMIN INHIBITOR; PROTEIN INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; SALICYLIC ACID; SORBITAN; SORBITAN TRIOLEATE; STEARIC ACID; SURFACTIN; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; GENE DELIVERY SYSTEM; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TOXICITY;

EID: 0346104870     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2003.10.001     Document Type: Review

References (58)

1. Agu R.U., Ugwoke M.I., Armand M., Kinget R., Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2:2001;198-209.
2. Patton J.S., Bukar J., Nagarajan S. Inhaled insulin. Adv. Drug Deliv. Rev. 35:1999;235-247.
3. Byron P.R., Patton J.S. Drug delivery via the respiratory tract. J. Aerosol. Med. 7:1994;49-75.
4. Weil A.T., Finberg N.E., Nelson J.M. Clinical and psychological effects of marijuana in man. Science. 162:1968;1234-1242.
5. Yu J., Chien Y.W. Pulmonary drug delivery: physiologic and mechanistic aspects. Crit. Rev. Ther. Drug Carrier Syst. 14:1997;395-453.
6. Hussain A., Yang T., Zaghloul A.A., Ahsan F. Pulmonary absorption of insulin mediated by tetradecyl-β-maltoside and dimethyl-β- cyclodextrin. Pharm. Res. 20:2003;1551-1557.
7. Aoyama T., Ino Y., Ozeki M., Oda M., Sato T., Koshiyama Y., Suzuki S., Fujita M. Pharmacological studies of FUT-175, nafamostat mesilate.1. Inhibition of protease activity in invitro and invivo experiment. Jpn. J. Pharmacol. 35:1984;203-227.
8. Takeyama M., Ishida T., Kokubu N., Komada F., Iwakawa S., Okumura K., Hori R. Enhanced bioavailability of subcutaneously injected insulin by pretreatment with ointment containing protease inhibitors. Pharm. Res. 8:1991;60-63.
9. Okumura K., Iwakawa S., Yoshida T., Seki T., Komada F. Intratracheal delivery of insulin: absorption from solution and aerosol by rat lung. Int. J. Pharm. 88:1992;63-73.
10. Komada F., Okumura K., Hori R. Fate of porcine and human insulin at the subcutaneous injection site II, In vitro degradation of insulins in the subcutaneous tissue of the rat. J. Pharmcobio-Dyn. 8:1985;33-40.
11. Raehs S.C., Sandow J., Wirth K., Merkle H.P. The adjuvant effect of bacitracin on nasal absorption of gonadorelin and buserelin in rats. Pharm. Res. 5:1988;689-693.
12. Yamamoto A., Umemori S., Muranishi S. Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and protease inhibitors in rats. J. Pharm. Pharmacol. 46:1994;14-18.
13. Fukuda Y., Tsuji T., Fujita T., Yamamoto A., Muranishi S. Susceptibility of insulin to proteolysis in rat lung homogenate and its protection from proteolysis by various protease inhibitors. Biol. Pharm. Bull. 18:1995;891-894.
14. 1,7]-eel calcitonin by various protease inhibitors in rats. Pharm. Res. 11:1994;909-913.
15. Kobayashi S., Konda S., Juni K. Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancers. Pharm. Res. 11:1994;1239-1243.
16. Morimoto K., Uehara Y., Iwanaga K., Kakemi M. Effects of sodium glycocholate and protease inhibitors on permeability of TRH and insulin across rabbit trachea. Pharm. Acta Helv. 74:2000;411-415.
17. Machida M., Hayashi M., Awazu S. The effects of absorption enhancers on the pulmonary absorption of recombinant human granulocyte colony-stimulation factor [rhG-CSF] in rats. Biol. Pharm. Bull. 23:2000;84-86.
18. Hersey S.J., Jackson R.T. Effect of bile salts on nasal permeability in vitro. J. Pharm. Sci. 76:1987;876-879.
19. Gordon G.S., Moses A.C., Silver R.D., Flier J.S., Carey M.C. Nasal absorption of insulin: enhancement by hydrophobic bile salts. Proc. Natl. Acad. Sci. 82:1985;7419-7423.
20. Johannson F., Hjertberg E., Eirefelt S., Tronde A., Bengtsson U.H. Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur. J. Pharm. Sci. 17:2002;63-71.
21. Heinemann L., Klappoth W., Rave K., Hompesch B., Linkeschowa R., Heis T. Intra-individual variability of metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care. 23:2000;1343-1347.
22. Kobayashi S., Konda S., Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm. Res. 13:1996;80-83.
23. Komada F., Iwakawa S., Yamamoto N., Sakakibara H., Okumura K. Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung. J. Pharm. Sci. 83:1994;863-867.
24. Yamamoto A., Hayakawa E., Lee V.H.L. Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit: implications in peptide delivery from nonoral route. Life Sci. 47:1990;2465-2474.
25. Yamamoto A., Hayakawa E., Kato Y., Nishiura A., Lee V.H.L. A mechanistic study on enhancement of rectal permeability to insulin in the albino rabbit. J. Pharmcol. Exp. Ther. 263:1992;25-31.
26. Mesiha M.S., Ponnapula S., Plakogiannis F. Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and α-tocopherol dispersions. Int. J. Pharm. 249:2002;1-5.
27. Hanson M., Gazdick G., Gahill J., Augustine M. Intranasal delivery of the peptide, salmon calcitonin. Davis S.S., Illum L., Tomlinson E. Delivery Systems for Peptide Drugs. 1986;233-242 Plenum Press, London.
28. Hirai S., Yashiki T., Mima H. Mechanisms for the enhancement of nasal absorption of insulin by surfactants. Int. J. Pharm. 9:1981;173-184.
29. Niven R.W., Byron P.R. Solute absorption from the air-ways of the isolated rat lung. II. Effect of surfactants on absorption of fluorescein. Pharm. Res. 7:1990;8-13.
30. Yamamoto A., Okumura S., Fukuda Y., Fukui M., Takahashi K., Muranishi S. Improvement of the pulmonary absorption of [Asu1,7]-eel calcitonin by various absorption enhancers and their pulmonary toxicity in rats. J. Pharm. Sci. 86:1997;1144-1146.
31. Fielding R.M., Abra R.M. Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig. Pharm. Res. 9:1992;220-223.
32. Tremblay G.M., Therien H.M., Rocheleau H., Cormier Y. Liposomal dexamethasone effectiveness in the treatment of hypersensitivity pneumonitis in mice. Eur. J. Clin. Invest. 23:1993;656-661.
33. Skubitz K.M., Anderson P.M. Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drugs. 11:2000;555-563.
34. Guillaume C., Delepine P., Mercier B., Gobin E., Leroy J.P., Morin V., Ferec C. Phosphonocationic lipids in protein delivery to mice lungs. J. Pharm. Sci. 89:2000;639-645.
35. Wright J.R. Clearance and recycling of pulmonary surfactant. Am. J. Physiol. 259:1990;L1-L12.
36. Ten R.M., Anderson P.M., Zein N.N., Temesgen Z., Clawson M.L., Weiss W. Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int. Immunopharmacol. 2:2002;333-344.
37. Liu F., Shao Z., Kildsig D.O., Mitra A.K. Pulmonary delivery of free and liposomal insulin. Pharm. Res. 10:1993;228-232.
38. Wiessner J.H., Hwang K.H. Binding of insulin to the external surface of liposomes: effect of surface curvature, temperature, and lipid composition. Biochem. Biophys. Acta. 689:1982;490-498.
39. Wiessner J.H., Mar H., Baskin D.S., Hwang K.H. Peptide-carrier interaction: introduction of liposome fusion and aggregation by insulin. J. Pharm. Sci. 75:1986;259-263.
40. Li Y., Mitra A.K. Effect of phospholipids chain length, concentration, charge, and vesicle size on pulmonary insulin absorption. Pharm. Res. 13:1996;76-79.
41. Matsubara K., Abe K., Irie T., Uekama K. Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats. J. Pharm. Sci. 84:1995;1295-1300.
42. Watanabe Y., Matsumoto Y., Kikuchi R., et al. Pharmacokinetics and pharmacodynamics of recombinant human granulocyte colony-stimulation factor [rhG-CSF] following intranasal administration to rabbits. J. Drug Targeting. 3:1995;231-238.
43. Schipper N.G.M., Verhoef J.C., De Lannoy et al L.M. Nasal administration of an ACTH[4-9] peptide analogue with dimethyl-β-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics. Br. J. Pharmacol. 110:1993;1335-1340.
44. Cooper A. Effect of cyclodextrins on the thermal stability of globular proteins. J. Am. Chem. Soc. 114:1992;9208-9209.
45. Horsky J., Pitha J. Inclusion complexes of proteins: interaction of cyclodextrins with peptides containing aromatic amino acids studied by competitive spectrophotometry. J. Inclu. Phenom. Mol. Recognit. Chem. 18:1994;291-300.
46. Beslow R., Yang Z., Ching R., Trojandt G., Odobel F. Sequence selective binding of peptides by artificial receptors in aqueous solution. J. Am. Chem. Soc. 120:1998;3536-3537.
47. Shao Z., Li Y., Mitra A.K. Cyclodextrins as mucosal absorption promoters of insulin III: pulmonary route of delivery. Eur. J. Pharm. Biopharm. 40:1994;283-288.
48. Shao Z., Krishnamoorty R., Mitra A.K. Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations. Pharm. Res. 9:1992;1157-1163.
49. Shen Z., Cheng Y., Zhang Q., Wei S., Li R., Wang K. Lanthanides enhance pulmonary absorption of insulin. Biol. Trace Elem. Res. 75:2000;215-225.
50. Cheng Y., Yao H.Y., Lin H.K., Lu J.F., Li R.C., Wang K. The events relating to lanthanide ions enhanced permeability of human erythrocyte membrane: binding, conformational change, phase transition, perforation and ion transport. Chem. Biol. Interact. 121:1999;267-289.
51. Cheng Y., Liu M.Z., Li R.C., Wang C., Bai C.L., Wang K. Gadolinium induces domain and pore formation of human erythrocyte membrane: an atomic force microscopic study. Biochim. Biophys. Acta. 1421:1999;249-260.
52. Suzuka T., Furuya A., Kamada A., Nishihata T. Effect of phenothiazine, disodium ethylenediaminetetraacetic acid and diethyl maleate on in vitro rat colonic transport of cefmetazole and inulin. J. Pharmacobio-Dyn. 10:1987;63-71.
53. Niven R.W., Whitcomb K.L., Shaner L.D., Ralph L.D., Habberfield A.D., Wilson J.V. Pulmonary absorption of polyethylene glycolated recombinant human granulocyte colony stimulating factor (PEGr-huG-CSF). J. Control. Release. 32:1994;177-189.
54. Suarez S., Contreras L.G., Sarubbi D., Flanders E., O'Toole D., Smart J., Hickey A.J. Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. Pharm. Res. 18:2001;1677-1684.
55. Garcia-Contreras L., Sarubbi D., Flanders E., Toole D.O., Smart J., Newcomer C., Hickey A.J. Immediate and short-term cellular and biochemical responses to pulmonary single-dose studies of insulin and H-MAP. Pharm. Res. 18:2001;1685-1693.
56. Adjei A., Doyle R., Johnson E., Pratt M., Finley R. Bioavailability of leuprolide following intratracheal administration to beagle dogs. Int. J. Pharm. 61:1990;135-144.
57. Adjei A., Hui J., Finley R., Lin T., Lancaster J., Fort F. Pulmonary bioavailability of leuprolide acetate following multiple dosing to beagle dogs: some pharmacokinetic and preclinical issues. Int. J. Pharm. 107:1994;57-66.
58. Wolff R.K. Safety of inhaled proteins for therapeutic use. J. Aerosol. Med. 11:1998;197-219.